Corneal penetration of levofloxacin into the human aqueous humour: A comparison with ciprofloxacin

Acta Ophthalmologica Scandinavica

Volumn 81, Issue 6, 2003, Pages 611-613

  Colin, Joseph ^a   Simonpoli, Sylvie ^a   Geldsetzer, Klaus ^b   Ropo, Auli ^c  

^a HÔPITAL PELLEGRIN   (France)

^b SANTEN PHARMACEUTICAL CO LTD   (Japan)

^c Santen Oy   (Finland)

Author keywords

Aqueous humour; Ciprofloxacin; Concentration; Fluoroquinolones; Levofloxacin; Ofloxacin

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA; DOSE RESPONSE; DRUG FORMULATION; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; GEOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARACENTESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME;

ADMINISTRATION, TOPICAL; AGED; ANTI-INFECTIVE AGENTS; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; CATARACT EXTRACTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; CORNEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OFLOXACIN; OPHTHALMIC SOLUTIONS;

EID: 0346220088     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1395-3907.2003.00173.x     Document Type: Article

References (11)

1. Davis R & Bryson HM (1994): Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47: 677-700.
2. Fujimoto T & Mitsuhashi S (1990): In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin. Chemotherapy 36: 268-276.
3. Graves A, Henry M, O'Brien TP, Hwang DG, Van Buskirk A & Trousdale MD (2001): In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones. Cornea 20: 301-305.
4. Hayakawa I, Atarashi S, Yokohama S, Imamura M, Sakano K, Furukawa M (1986): Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother 29: 163-164.
5. Mitsui Y, Ooishi M, Sasaki K & Ohashi Y (1995): AQCmax as a pharmacokinetic parameter of ophthalmic solution. J Eye 12: 783-786.
6. Neu HC & Chin NX (1989): In vitro activity of S-ofloxacin. Antimicrob Agents Chemother 33: 1105-1107.
7. O'hÉineacháin R (2003): ESCRS study gears up to slash endophthalmitis rate. ESONT Eurotimes 1 (2): http://www.escrs.org/ESONT/ESONT1-2/ESONT_ET.htm
8. Ross DL & Riley CM (1990): Aqueous solubilities of some variously substituted quinolone antimicrobials. Int J Pharm 63: 237-250.
9. Schwab IR, Friedlander M, McCulley J, Lichtenstein SJ, Moran CT & the Levofloxacin Bacterial Conjunctivitis Active Control Study Group (2003): A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 110: 457-465.
10. Shapiro SS & Wilk MB (1965): An analysis of variance test for normality (complete samples). Biometrika 52 (3, 4): 591-611.
11. Yamada M, Mochizuki H, Yamada K, Kawa M, Mashima Y (2002): Aqueous humour levels of topically applied levofloxacin in human eyes. Curr Eye Res 24: 403-406.